Vaccine for kids: Zydus Cadila receives order to supply 1 crore COVID-19 jabs to govt at Rs 265 per dose

ZyCoV-D is the first DNA plasmid vaccine in the world for human use, developed indigenously by the company.

Published: 08th November 2021 06:03 PM  |   Last Updated: 08th November 2021 08:07 PM   |  A+A-

COVID Vaccine

For representational purposes (Photo | AP)

By PTI

NEW DELHI: Drug firm Zydus Cadila on Monday said it has received an order to supply one crore doses of its COVID-19 vaccine, ZyCoV-D, to the Indian government at Rs 265 per dose.

"Zydus Cadila has received an order to supply one crore doses of ZyCoV-D, the world's first Plasmid DNA Vaccine, to the Government of India at Rs 265 per dose and the needle-free applicator being offered at Rs 93 per dose, excluding GST," the pharma firm said in a regulatory filing The pricing has been decided in consultation with the central government, it added.

The vaccine will be administered using a needle-free applicator as opposed to traditional syringes.

The PharmaJet is a needle-free applicator to ensure painless intradermal vaccine delivery which also leads to a significant reduction in any kind of major side effects.

"We are happy to support the government's vaccination programme with ZyCoV-D. The needle-free application of the vaccination, we hope, will motivate many more to vaccinate and safeguard themselves from COVID-19, especially children and young adults in the age group of 12 to 18 years," Zydus Cadila MD Sharvil Patel said.

ZyCoV-D is the first DNA plasmid vaccine in the world for human use, developed indigenously by the company against the COVID-19 virus, Zydus Cadila said.

The vaccine has shown good stability at temperatures of around 25 degrees for at least three months.

The thermostability of the vaccine will help in easy transportation and storage of the vaccine without any problems of fluctuations in temperature, it added.

ZyCoV-D is the first vaccine cleared by India's drug regulator for inoculation of those aged 12 years and above.

The three doses of ZyCoV-D, are to be administered 28 days apart.

The vaccine was given emergency use authorization (EUA) by the Indian drug regulator on August 20, this year.

The company has also sought approval for the two-dose regimen of the vaccine.


Comments

Disclaimer : We respect your thoughts and views! But we need to be judicious while moderating your comments. All the comments will be moderated by the newindianexpress.com editorial. Abstain from posting comments that are obscene, defamatory or inflammatory, and do not indulge in personal attacks. Try to avoid outside hyperlinks inside the comment. Help us delete comments that do not follow these guidelines.

The views expressed in comments published on newindianexpress.com are those of the comment writers alone. They do not represent the views or opinions of newindianexpress.com or its staff, nor do they represent the views or opinions of The New Indian Express Group, or any entity of, or affiliated with, The New Indian Express Group. newindianexpress.com reserves the right to take any or all comments down at any time.